Memory Impairment is Associated with Serum Methylarginines in Older Adults

Current Alzheimer Research

Volumn 11, Issue 1, 2014, Pages 97-106

  McEvoy, Mark ^a   Schofield, Peter ^b   Smith, Wayne ^c   Agho, Kingsley ^d   Mangoni, Arduino A ^e,f   Soiza, Roy L ^e,f   Peel, Roseanne ^a   Attia, John ^a,g  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c NEW SOUTH WALES MINISTRY OF HEALTH   (Australia)

^d UNIVERSITY OF WESTERN SYDNEY   (Australia)

^e UNIVERSITY OF ABERDEEN   (United Kingdom)

^f WOODEND HOSPITAL   (United Kingdom)

^g JOHN HUNTER HOSPITAL   (Australia)

Author keywords

ADMA; Alzheimer's disease; Memory impairment; Methylarginines; Nitric oxide; Older adults; SDMA

Indexed keywords

6 N N DIMETHYLARGININE; ARGININE; CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; UNCLASSIFIED DRUG;

ADULT; AGED; ALCOHOL CONSUMPTION; ANGINA PECTORIS; APTITUDE TEST; ARTICLE; CLINICAL STUDY; CORONARY ARTERY BYPASS GRAFT; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; EDUCATIONAL STATUS; FEMALE; GENERAL PRACTITIONER; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERTENSION; LIFESTYLE; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MEMORY COMPLAINT QUESTIONNAIRE; MEMORY DISORDER; MIDDLE AGED; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; RISK FACTOR; SELF CONCEPT; SMOKING; THYROID DISEASE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ARGININE; ATRIAL FIBRILLATION; COHORT STUDIES; DIABETES MELLITUS; EDUCATIONAL STATUS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MEMORY DISORDERS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUROPSYCHOLOGICAL TESTS; ODDS RATIO; SEVERITY OF ILLNESS INDEX;

EID: 84891819830     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/15672050113106660178     Document Type: Article

References (58)

1. World Health Organisation. Dementia Fact sheet No.362 2012. Available from: http://www.who.int/mediacentre/factsheets/fs362/en/index.html.
2. Zhao B. Nitric oxide in neurodegenerative diseases. Front Biosci 10: 454-61 (2005).
3. Paul V, Ekambaram P. Involvement of nitric oxide in learning & memory processes. Indian J Med Res 133(5): 471 (2011).
4. Schuman EM, Madison DV. A requirement for the intercellular messenger nitric oxide in long-term potentiation. Science 254(5037): 1503-6 (1991).
5. Bliss TVP, Collingridge GL. A synaptic model of memory: longterm potentiation in the hippocampus. Nature 361(6407): 31-9 (1993).
6. Moncada S, Higgs A. The l-arginine-nitric oxide pathway. N Engl J Med 329(27): 2002-12 (1993).
7. Dawson VL, Dawson TM. Nitric oxide neurotoxicity. J Chem Neuroanat 10(3-4): 179 (1996).
8. Thorns V, Hansen L, Masliah E. nNOS expressing neurons in the entorhinal cortex and hippocampus are affected in patients with Alzheimer's disease. Exp Neurol 150(1): 14-20 (1998).
9. Lüth HJ, Holzer M, Gärtner U, Staufenbiel M, Arendt T. Expression of endothelial and inducible NOS-isoforms is increased in Alzheimer's disease, in APP23 transgenic mice and after experimental brain lesion in rat: evidence for an induction by amyloid pathology. Brain Res 913(1): 57-67 (2001).
10. Qiu C, Xu W, Fratiglioni L. Vascular and psychosocial factors in Alzheimer's disease: epidemiological evidence toward intervention. J Alzheimers Dis 20(3): 689-97 (2010).
11. Brayne C, Matthews FE, McGee MA, Jagger C. Health and ill health in the older population in England and Wales The Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Age Ageing 30(1): 53-62 (2001).
12. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in communitydwelling older persons. Neurology 69(24): 2197-204 (2007).
13. De La Torre J, Cada A, Nelson N, Davis G, Sutherland R, Gonzalez-Lima F. Reduced cytochrome oxidase and memory dysfunction after chronic brain ischemia in aged rats. Neurosci Lett 223(3): 165-8 (1997).
14. Johnson KA, Albert MS. Perfusion abnormalities in prodromal AD. Neurobiol Aging 21(2): 289-92 (2000).
15. Fliser D. Asymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin'to a global cardiovascular risk molecule. Eur J Clin Invest 35(2): 71-9 (2005).
16. Segarra G, Medina P, Vila JM, Chuan P, Domenech C, Torondel B, et al. Inhibition of nitric oxide activity by arginine analogs in human renal arteries. Am J Hypertens 14(11): 1142-8 (2001).
17. Segarra G, Medina P, Ballester R, Lluch P, Aldasoro M, Vila J, et al. Effects of some guanidino compounds on human cerebral arteries. Stroke 30(10): 2206-11 (1999).
18. Selley ML. Homocysteine increases the production of asymmetric dimethylarginine in cultured neurons. J Neurosci Res 77(1): 90-3 (2004).
19. Caplin B, Leiper J. Endogenous Nitric Oxide Synthase Inhibitors in the Biology of Disease Markers, Mediators, and Regulators? Arterioscler Thromb Vasc Biol 32(6): 1343-53 (2012).
20. Leong T, Zylberstein D, Graham I, Lissner L, Ward D, Fogarty J, et al. Asymmetric Dimethylarginine Independently Predicts Fatal and Nonfatal Myocardial Infarction and Stroke in Women 24-Year Follow-Up of the Population Study of Women in Gothenburg. Arterioscler Thromb Vasc Biol 28(5): 961-7 (2008).
21. Juonala M, Viikari JS, Alfthan G, Marniemi J, Kähönen M, Taittonen L, et al. Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the cardiovascular risk in young Finns study. Circulation 116(12): 1367-73 (2007).
22. Maas R, Schulze F, Baumert J, Löwel H, Hamraz K, Schwedhelm E, et al. Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Region Augsburg study and experimental data. Clin Chem 53(4): 693-701 (2007).
23. Young JM, Terrin N, Wang X, Greene T, Beck GJ, Kusek JW, et al. Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol 4(6): 1115-20 (2009).
24. Böger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 119(12): 1592-600 (2009).
25. Closs EI, Basha FZ, Habermeier A, Förstermann U. Interference ofL-Arginine Analogues withL-Arginine Transport Mediated by the y+Carrier hCAT-2B. Nitric Oxide. 1997 2;1(1):65-73.
26. Meinitzer A, Kielstein JT, Pilz S, Drechsler C, Ritz E, Boehm BO, et al. Symmetrical and Asymmetrical Dimethylarginine as Predictors for Mortality in Patients Referred for Coronary Angiography: The Ludwigshafen Risk and Cardiovascular Health Study. Clin Chem 57(1): 112-21 (2011).
27. Mangoni AA. The emerging role of symmetric dimethylarginine in vascular disease. Adv Clin Chem 48: 73-94 (2009).
28. Mamatha SN, Nagaraja D, Philip M, Christopher R. Asymmetric dimethylarginine as a risk marker for early-onset ischemic stroke in Indian population. Clin Chim Acta 412(1): 139-42 (2011).
29. Pikula A, Böger RH, Beiser AS, Maas R, DeCarli C, Schwedhelm E, et al. Association of plasma ADMA levels with MRI markers of vascular brain injury. Stroke 40(9): 2959-64 (2009).
30. Notsu Y, Nabika T, Bokura H, Suyama Y, Kobayashi S, Yamaguchi S, et al. Evaluation of asymmetric dimethylarginine and homocysteine in microangiopathy-related cerebral damage. Am J Hypertens 22(3): 257-62 (2008).
31. Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, Martens-Lobenhoffer J, et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 37(8): 2024-9 (2006).
32. Faraci FM, Brian Jr JE, Heistad DD. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am J Physiol Heart Circ Physiol 269(5): H1522-H7 (1995).
33. Austin SA, Santhanam AV, Katusic ZS. Endothelial Nitric Oxide Modulates Expression and Processing of Amyloid Precursor ProteinNovelty and Significance. Circ Res 107(12): 1498-502 (2010).
34. Selley M. Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease. Neurobiol Aging 24(7): 903-7 (2003).
35. Arlt S, Schulze F, Eichenlaub M, Maas R, Lehmbeck JT, Schwedhelm E, et al. Asymmetrical dimethylarginine is increased in plasma and decreased in cerebrospinal fluid of patients with Alzheimer's disease. Dement Geriatr Cogn Disord 26(1): 58-64 (2008).
36. Mulder C, Wahlund LO, Blomberg M, De Jong S, Van Kamp G, Scheltens P, et al. Alzheimer's disease is not associated with altered concentrations of the nitric oxide synthase inhibitor asymmetric dimethylarginine in cerebrospinal fluid. J Neural Transm 109(9): 1203-8 (2002).
37. Abe T, Tohgi H, Murata T, Isobe C, Sato C. Reduction in asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in the cerebrospinal fluid during aging and in patients with Alzheimer's disease. Neurosci Lett 312(3): 177-9 (2001).
38. Smith MA, Vasák M, Knipp M, Castellani RJ, Perry G. Dimethylargininase, a nitric oxide regulatory protein, in Alzheimer disease. Free Radic Biol Med 25(8): 898-902 (1998).
39. Wadham C, Mangoni AA. Dimethylarginine dimethylaminohydrolase regulation: a novel therapeutic target in cardiovascular disease. Expert Opin Drug Met 5(3): 303-19 (2009).
40. Schofield PW, Lee SJ, Lewin TJ, Lyall G, Moyle J, Attia J, et al. The Audio Recorded Cognitive Screen (ARCS): a flexible hybrid cognitive test instrument. J Neurol Neurosur Ps 81(6): 602-7 (2010).
41. Crook TH, Feher EP, Larrabee GJ. Assessment of memory complaint in age-associated memory impairment: the MAC-Q. Int Psychogeriatr 4(2): 165-76 (1992).
42. Anothaisintawee T, Attia J, Nickel JC, Thammakraisorn S, Numthavaj P, McEvoy M, et al. Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis. JAMA 305(1):78-86 (2011).
43. Bedford MT, Richard S. Arginine methylation: an emerging regulatorof protein function. Mol Cell 18(3): 263-72 (2005).
44. McEvoy M, Smith W, D'Este C, Duke J, Peel R, Schofield P, et al. Cohort profile: The Hunter Community Study. Int J Epidemiol 39(6): 1452-63 (2010).
45. Chapman PF, Atkins CM, Allen MT, Haley JE. Inhibition of nitric oxide synthesis impairs two different forms of learning. Neuroreport 3(7): 567-70 (1992).
46. Mogensen J, Wortwein G, Hasman A, Nielsen P, Wang Q. Functional and neurochemical profile of place learning after Lnitro-arginine in the rat. Neurobiol Learn Mem 63(1): 54-65 (1995).
47. Ohno M, Yamamoto T, Watanabe S. Intrahippocampal administration of the NO synthase inhibitorl-NAME prevents working memory deficits in rats exposed to transient cerebral ischemia. Brain Res 634(1): 173-7 (1994).
48. Wiley JL, Willmore C. Effects of nitric oxide synthase inhibitors on timing and short-term memory in rats. Behav Pharmacol 11(5): 421-9 (2000).
49. Bannerman D, Chapman P, Kelly P, Butcher S, Morris R. Inhibition of nitric oxide synthase does not impair spatial learning. J Neurosci 14(12): 7404-14 (1994).
50. Cobb BL, Ryan KL, Frei MR, Guel-Gome V, Andrew Mickley G. Chronic administration of L-NAME in drinking water alters working memory in rats. Brain Res Bull 38(2):203-7 (1995).
51. Bannerman D, Chapman P, Kelly P, Butcher S, Morris R. Inhibition of nitric oxide synthase does not prevent the induction of long-term potentiation In vivo. J Neurosci 14(12): 7415-25 (1994).
52. Traystman RJ, Moore LE, Helfaer MA, Davis S, Banasiak K, Williams M, et al. Nitro-L-arginine analogues: dose-and timerelated nitric oxide synthase inhibition in brain. Stroke 26(5): 864-9 (1995).
53. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87(1): 315-424 (2007).
54. Tran MH, Yamada K, Olariu A, Mizuno M, Ren XH, Nabeshima T. Amyloid b-peptide induces nitric oxide production in rat hippocampus: association with cholinergic dysfunction and amelioration by inducible nitric oxide synthase inhibitors. The FASEB J 15(8): 1407-9 (2001).
55. Lee J, Sayegh J, Daniel J, Clarke S, Bedford MT. PRMT8, a New Membrane-bound Tissue-specific Member of the Protein Arginine Methyltransferase Family. J Biol Chem 280(38): 32890-6 (2005).
56. Richard S, Morel M, Cléroux P. Arginine methylation regulates IL-2 gene expression: a role for protein arginine methyltransferase 5 (PRMT5). Biochem J 388(Pt 1): 379 (2005).
57. Zoccali C, Maas R, Cutrupi S, Pizzini P, Finocchiaro P, Cambareri F, et al. Asymmetric dimethyl-arginine (ADMA) response to inflammation in acute infections. Nephrol Dial Transplant 22(3): 801-6 (2007).
58. Caglar K, Yilmaz MI, Sonmez A, Cakir E, Kaya A, Acikel C, et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int 70(4): 781-7 (2006).